Get the Stockscreener App
27.37
1.12%
-0.31
Pre-market:
27.40
0.03
+0.11%
Veracyte Inc stock is traded at $27.37, with a volume of 1.54M.
It is down -1.12% in the last 24 hours and up +2.97% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$27.68
Open:
$27.77
24h Volume:
1.54M
Relative Volume:
1.11
Market Cap:
$2.14B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-36.49
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
+15.78%
1M Performance:
+2.97%
6M Performance:
-34.14%
1Y Performance:
-8.68%
1-Day Range:
$27.35
$28.69
1-Week Range:
$23.35
$28.69
52-Week Range:
$22.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
27.37 | 1.88B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Candlestick Signal Suggests Reversal in Veracyte Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Veracyte stock price target lowered to $28 from $29 at Morgan Stanley - Investing.com Nigeria
Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns - TipRanks
Veracyte price target lowered to $28 from $29 at Morgan Stanley - TipRanks
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript - Insider Monkey
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones - TipRanks
Veracyte Receives Buy Rating and $37 Price Target from Guggenheim Analyst - AInvest
Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care - Eastern Progress
Veracyte (VCYT) Q2 Revenue Jumps 14% - AOL.com
Veracyte stock rating reiterated at Outperform by William Blair - Investing.com India
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls - Investing.com Canada
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls By Investing.com - Investing.com South Africa
Veracyte's 2025 Q2 Financial Performance and Strategic Momentum: A Deep Dive into Diagnostic Innovation and Oncology Expansion - AInvest
Veracyte Announces Second Quarter 2025 Financial Results - BioSpace
Veracyte's 2025 Earnings Call: A Catalyst-Driven Path to Sustained Double-Digit Growth and 25%+ Adjusted EBITDA Margins - AInvest
Veracyte Reports Strong Q2 2025 Revenue Growth - TipRanks
Veracyte’s Revenue Growth Outpaces Forecasts And Lifts Guidance - Finimize
Veracyte: Q2 Earnings Snapshot - San Francisco Chronicle
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Veracyte Q2 2025 slides: Decipher drives 14% revenue growth, EBITDA margins expand - Investing.com Nigeria
Veracyte Q2 revenue rises 14%, beats expectations - MarketScreener
Veracyte Inc (VCYT) Q2 2025 Earnings: Revenue Surpasses Estimates at $130.2M, Reports GAAP Net Loss - GuruFocus
Veracyte shares surge as Q2 profits quadruple expectations By Investing.com - Investing.com South Africa
Veracyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Veracyte shares surge as Q2 profits quadruple expectations - Investing.com
Veracyte Inc earnings beat by $0.33, revenue topped estimates - Investing.com Canada
Veracyte reports Q2 EPS 44c, consensus 30c - TipRanks
Veracyte sees FY25 revenue $477M-$483M, consensus $491.92M - TipRanks
Earnings Flash (VCYT) Veracyte, Inc. Reports Q2 Revenue $130.2M, vs. FactSet Est of $121.0M - MarketScreener
Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.44 per Share, vs. FactSet Est of $0.26 - MarketScreener
Press Release: Veracyte Announces Second Quarter 2025 Financial Results - 富途牛牛
Veracyte Q2 2025 Earnings Call Transcript - MarketBeat
Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For - Yahoo Finance
What catalysts could drive Veracyte Inc. stock higher in 2025Invest smarter with daily market updates - Jammu Links News
How does Veracyte Inc. compare to its industry peersFree Stock Market Trend Analysis - Jammu Links News
How does Veracyte Inc. generate profit in a changing economyMaximize portfolio growth with strategic plans - Jammu Links News
How many analysts rate Veracyte Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
Should I hold or sell Veracyte Inc. stock in 2025Achieve consistent double-digit growth rates - Jammu Links News
What is the risk reward ratio of investing in Veracyte Inc. stockUnlock exclusive investment alerts - Jammu Links News
How strong is Veracyte Inc. company’s balance sheetOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Veracyte Inc. stockSuperior risk-adjusted returns - Jammu Links News
What drives Veracyte Inc. stock priceUnprecedented market success - Jammu Links News
What institutional investors are buying Veracyte Inc. stockInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Veracyte Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
When is Veracyte Inc. stock expected to show significant growthCapitalize on market momentum for maximum gains - Jammu Links News
What are analysts’ price targets for Veracyte Inc. in the next 12 monthsSuperior trading gains - Jammu Links News
How Veracyte Inc. stock performs during market volatilityStep-by-Step Stock Investment Guide Gains Popularity - beatles.ru
How volatile is Veracyte Inc. stock compared to the marketLow Risk Updates For Beginners - Jammu Links News
Morgan Stanley Downgrades Iridium Communications to Overweight with $37 PT. - AInvest
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bhanji Muna | Director |
Jun 13 '25 |
Sale |
26.67 |
4,589 |
122,367 |
29,989 |
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):